Interpreting oral fluid drug results in prisoners: monitoring current drug intake and detection times for drugs self-administered prior to detention
Although urine is the most common matrix for prisoner drug testing, oral fluid offers a possible alternative. Identifying new drug intake by a prisoner results in negative sanctions. Detection times in oral fluid after chronic drug intake may be extended. Within the prison, admission population is chronic drug users. Our aim was to investigate detection windows for drugs of abuse in oral fluid from prisoners.
Nineteen frequent drug-abusing prisoners provided oral fluid and urine at admission and each morning thereafter for 9 consecutive days.
The most positive findings were for amphetamine/methamphetamine, cannabis and benzodiazepines. Maximum detection times in oral fluid were ≥ 9 days for diazepam, methadone and methamphetamine, with corresponding urinary detection times of ≥ 9, 7 and 6 days, respectively. Maximum oral fluid detection times were 9 days for clonazepam, 8 for oxazepam, 3 for amphetamine and nitrazepam, and 2 for tetrahydrocannabinol, with positive urinary detection times of 8, ≥ 9, 5, 7 and ≥ 9 days, respectively. Cocaine, morphine and 6-acetylmorphine were all positive only 1 day in oral fluid; cocaine and morphine were positive 1 and 2 days, respectively, in urine, while 6-acetylmorphine was not detected in urine.
We confirmed oral fluid as a viable matrix for monitoring drugs of abuse in prisoners. Windows of detection for benzodiazepines and amphetamines were up to 1 week, which is an important consideration for evaluating oral fluid drug testing results. Some likely new drug exposures were observed based on urine and oral fluid drug results, but there were few data to guide these interpretations.
KeywordsOral fluid/urine Detection time Drugs of abuse Prisoners Detection window
We would like to thank Eirik Trøgstad, Svein Pettersen, Frank Kaasa, Leif Skaug and Stig Tore Kopperud for organizing the inclusion of prisoners in the project and excellent sample collection.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest. This study has not received any external financial support.
The Norwegian Regional Committee for Medical and Health Research Ethics approved the study. Participation was voluntary, and participants could withdraw at any time without penalty. Written informed consent from 19 inmates from three prisons was obtained prior to inclusion after fully informing participants about the study.
- 8.Drummer OH (2006) Drug testing in oral fluid. Clin Biochem Rev 27:147–159 (PMID: 17268583)Google Scholar
- 10.Miller KL, Puet BL, Roberts A, Hild C, Carter J, Black DL (2017) Urine drug testing results and paired oral fluid comparison from patients enrolled in long-term medication-assisted treatment in Tennessee. J Subst Abuse Treat 76:36–42. https://doi.org/10.1016/j.jsat.2017.01.005 CrossRefGoogle Scholar
- 14.Conermann T, Gosalia AR, Kabazie AJ, Moore C, Miller K, Fetsch M, Irvan D (2014) Utility of oral fluid in compliance monitoring of opioid medications. Pain Physician 17:63–70 (PMID: 24452646)Google Scholar
- 15.Vindenes V, Lund HME, Andresen W, Gjerde H, Ikdahl SE, Christophersen AS, Øiestad EL (2012) Detection of drugs of abuse in simultaneously collected oral fluid, urine and blood from Norwegian drug drivers. Forensic Sci Int 219:165–171. https://doi.org/10.1016/j.forsciint.2012.01.001 CrossRefGoogle Scholar
- 16.Schepers RJF, Oyler JM, Joseph RE Jr, Cone EJ, Moolchan ET, Huestis MA (2003) Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem 49:121–132. https://doi.org/10.1373/49.1.121 CrossRefGoogle Scholar
- 22.Scheidweiler KB, Spargo EAK, Kelly TL, Cone EJ, Barnes AJ, Huestis MA (2010) Pharmacokinetics of cocaine and metabolites in human oral fluid and correlation with plasma concentrations after controlled administration. Ther Drug Monit 32:628–637. https://doi.org/10.1097/FTD.0b013e3181f2b729 CrossRefGoogle Scholar
- 23.Smink BE, Hofman BJA, Dijkhuizen A, Lusthof KJ, de Gier JJ, Egberts ACG, Uges DRA (2008) The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam. Br J Clin Pharmacol 66:556–560. https://doi.org/10.1111/j.1365-2125.2008.03252.x CrossRefGoogle Scholar
- 29.Nordal K, Øiestad EL, Enger A, Christophersen AS, Vindenes V (2015) Detection times of diazepam, clonazepam, and alprazolam in oral fluid collected from patients admitted to detoxification, after high and repeated drug intake. Ther Drug Monit 37:451–460. https://doi.org/10.1097/FTD.0000000000000174 CrossRefGoogle Scholar
- 33.Dahl SR, Olsen KM, Strand DH (2012) Determination of γ-hydroxybutyrate (GHB), β-hydroxybutyrate (BHB), pregabalin, 1,4-butane-diol (1,4BD) and γ-butyrolactone (GBL) in whole blood and urine samples by UPLC-MSMS. J Chromatogr B 885–886:37–42. https://doi.org/10.1016/j.jchromb.2011.12.009 CrossRefGoogle Scholar
- 34.Hegstad S, Øiestad EL, Johansen U, Christophersen AS (2006) Determination of benzodiazepines in human urine using solid-phase extraction and high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. J Anal Toxicol 30:31–37. https://doi.org/10.1093/jat/30.1.31 CrossRefGoogle Scholar
- 41.Jang M, Chang H, Yang W, Choi H, Kim E, Yu BH, Oh Y, Chung H (2013) Development of an LC-MS/MS method for the simultaneous determination of 25 benzodiazepines and zolpidem in oral fluid and its application to authentic samples from regular drug users. J Pharm Biomed Anal 74:213–222. https://doi.org/10.1016/j.jpba.2012.11.002 CrossRefGoogle Scholar
- 43.Kangas L, Allonen H, Lammintausta R, Salonen M, Pekkarinen A (1979) Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. Acta Pharmacol Toxicol 45:20–24. https://doi.org/10.1111/j.1600-0773.1979.tb02354.x CrossRefGoogle Scholar
- 45.Logan BK (2002) Methamphetamine—effects on human performance and behavior. Forensic Sci Rev 14:133–151 (PMID: 26256490)Google Scholar